These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 18399960)

  • 1. Comparison of neuroprotective and neurorestorative capabilities of rasagiline and selegiline against lactacystin-induced nigrostriatal dopaminergic degeneration.
    Zhu W; Xie W; Pan T; Jankovic J; Li J; Youdim MB; Le W
    J Neurochem; 2008 Jun; 105(5):1970-8. PubMed ID: 18399960
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prevention and restoration of lactacystin-induced nigrostriatal dopamine neuron degeneration by novel brain-permeable iron chelators.
    Zhu W; Xie W; Pan T; Xu P; Fridkin M; Zheng H; Jankovic J; Youdim MB; Le W
    FASEB J; 2007 Dec; 21(14):3835-44. PubMed ID: 17690154
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comprehensive review of rasagiline, a second-generation monoamine oxidase inhibitor, for the treatment of Parkinson's disease.
    Chen JJ; Swope DM; Dashtipour K
    Clin Ther; 2007 Sep; 29(9):1825-49. PubMed ID: 18035186
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Proteasome inhibition modeling nigral neuron degeneration in Parkinson's disease.
    Xie W; Li X; Li C; Zhu W; Jankovic J; Le W
    J Neurochem; 2010 Oct; 115(1):188-99. PubMed ID: 20649845
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Multiple molecular pathways are involved in the neuroprotection of GDNF against proteasome inhibitor induced dopamine neuron degeneration in vivo.
    Du Y; Li X; Yang D; Zhang X; Chen S; Huang K; Le W
    Exp Biol Med (Maywood); 2008 Jul; 233(7):881-90. PubMed ID: 18445767
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Rasagiline in daily clinical use. Results of a treatment study of Parkinson patients with a combination treatment].
    Jost WH; Klasser M; Reichmann H
    Fortschr Neurol Psychiatr; 2008 Oct; 76(10):594-9. PubMed ID: 18833504
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neuroprotection by rasagiline in thiamine deficient rats.
    Eliash S; Dror V; Cohen S; Rehavi M
    Brain Res; 2009 Feb; 1256():138-48. PubMed ID: 19103184
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Monamine oxidase inhibitors: current and emerging agents for Parkinson disease.
    Fernandez HH; Chen JJ
    Clin Neuropharmacol; 2007; 30(3):150-68. PubMed ID: 17545750
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neuroprotective rather than neurorescue or neurorestorative effect of selegiline against MPTP-induced dopaminergic toxicity.
    Wu WR; Zhu XZ; Guan HJ; Wang RG; Ji XQ
    Zhongguo Yao Li Xue Bao; 1999 Feb; 20(2):146-50. PubMed ID: 10437162
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neuroprotection of rapamycin in lactacystin-induced neurodegeneration via autophagy enhancement.
    Pan T; Kondo S; Zhu W; Xie W; Jankovic J; Le W
    Neurobiol Dis; 2008 Oct; 32(1):16-25. PubMed ID: 18640276
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel D3 dopamine receptor-preferring agonist D-264: Evidence of neuroprotective property in Parkinson's disease animal models induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine and lactacystin.
    Li C; Biswas S; Li X; Dutta AK; Le W
    J Neurosci Res; 2010 Aug; 88(11):2513-23. PubMed ID: 20623619
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bifunctional drug derivatives of MAO-B inhibitor rasagiline and iron chelator VK-28 as a more effective approach to treatment of brain ageing and ageing neurodegenerative diseases.
    Youdim MB; Fridkin M; Zheng H
    Mech Ageing Dev; 2005 Feb; 126(2):317-26. PubMed ID: 15621213
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rasagiline: a novel anti-Parkinsonian monoamine oxidase-B inhibitor with neuroprotective activity.
    Weinreb O; Amit T; Bar-Am O; Youdim MB
    Prog Neurobiol; 2010 Nov; 92(3):330-44. PubMed ID: 20600573
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rasagiline: neurodegeneration, neuroprotection, and mitochondrial permeability transition.
    Youdim MB; Bar Am O; Yogev-Falach M; Weinreb O; Maruyama W; Naoi M; Amit T
    J Neurosci Res; 2005 Jan 1-15; 79(1-2):172-9. PubMed ID: 15573406
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rasagiline (TVP-1012): a new selective monoamine oxidase inhibitor for Parkinson's disease.
    Guay DR
    Am J Geriatr Pharmacother; 2006 Dec; 4(4):330-46. PubMed ID: 17296539
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recent advances in Parkinson's disease therapy: use of monoamine oxidase inhibitors.
    Henchcliffe C; Schumacher HC; Burgut FT
    Expert Rev Neurother; 2005 Nov; 5(6):811-21. PubMed ID: 16274338
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Activation of tyrosine kinase receptor signaling pathway by rasagiline facilitates neurorescue and restoration of nigrostriatal dopamine neurons in post-MPTP-induced parkinsonism.
    Sagi Y; Mandel S; Amit T; Youdim MB
    Neurobiol Dis; 2007 Jan; 25(1):35-44. PubMed ID: 17055733
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neuroprotection by iron chelator against proteasome inhibitor-induced nigral degeneration.
    Zhang X; Xie W; Qu S; Pan T; Wang X; Le W
    Biochem Biophys Res Commun; 2005 Jul; 333(2):544-9. PubMed ID: 15950935
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mechanism of neuroprotective action of the anti-Parkinson drug rasagiline and its derivatives.
    Mandel S; Weinreb O; Amit T; Youdim MB
    Brain Res Brain Res Rev; 2005 Apr; 48(2):379-87. PubMed ID: 15850677
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neuroprotective effect of rasagiline in a rodent model of Parkinson's disease.
    Blandini F; Armentero MT; Fancellu R; Blaugrund E; Nappi G
    Exp Neurol; 2004 Jun; 187(2):455-9. PubMed ID: 15144871
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.